Evidence map›Paper›PMID 38472446›Full record

ArticleCellular and molecular life sciences : CMLS2024

Crosstalk between purinergic receptor P2Y

Dominik Klaver, Hubert Gander, Beatrice Frena, Marco Amato, Martin Thurnher

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Dominik KlaverImmunotherapy Unit, Department of Urology, Medical University of Innsbruck, Innrain 66a, Innsbruck, 6020, Austria.ORCID http://orcid.org/0000-0002-3367-0823
Hubert GanderImmunotherapy Unit, Department of Urology, Medical University of Innsbruck, Innrain 66a, Innsbruck, 6020, Austria.
Beatrice FrenaImmunotherapy Unit, Department of Urology, Medical University of Innsbruck, Innrain 66a, Innsbruck, 6020, Austria.
Marco AmatoCentral Institute for Blood Transfusion & Department of Immunology (ZIB), Tirol Kliniken GmbH, Innsbruck, Austria.
Martin ThurnherImmunotherapy Unit, Department of Urology, Medical University of Innsbruck, Innrain 66a, Innsbruck, 6020, Austria. martin.thurnher@i-med.ac.at.ORCID http://orcid.org/0000-0001-9940-7326
Innsbruck Medical University · ATTirol Kliniken · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

P2Y

Indexed as

Receptors, CXCR4Signal TransductionCell LineChemokine CXCL12Cyclic AMPHumansMacrophagesReceptors, CXCRReceptors, PurinergicReceptors, Purinergic P2ACKR3 protein, humanChemokine CXCL12CXCR4 protein, humanCyclic AMPP2RY11 protein, humanReceptors, CXCRReceptors, CXCR4Receptors, PurinergicReceptors, Purinergic P2CCL20CXCR4CXCR7Cyclic AMPEGFRP2Y11PDE4

Identifiers

PMID38472446
PMCPMC10933201
OpenAlexW4392759478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.